<DOC>
	<DOCNO>NCT02269800</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety Benzalkonium Chloride Solution clear oral colonized bacterium hospitalize patient COPD .</brief_summary>
	<brief_title>An Efficacy Study BCS Clearing Oral Colonized Bacterium Hospitalized Patients With COPD</brief_title>
	<detailed_description>This randomize , double-blind , parallel , single-center , exploratory trial . 60 patient randomize two treatment : benzalkonium chloride solution treatment normal saline treatment.The purpose study evaluate efficacy safety benzalkonium chloride solution clear oral colonized bacterium hospitalize patient COPD .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Benzalkonium Compounds</mesh_term>
	<criteria>1 . COPD patient hospitalize . 2 . Aged from18 70 year ( include 18 70 ) . 3 . Patients participate trial sign ICFs . 4 . Patients good understanding , could conduct study investigator . 1 . History mouthwash allergy , allergic rhinitis dermatitis . 2 . Patients oral ulcer , severe periodontal disease , oral mucosal lesion oral cancer , patient receive special oral clean . 3 . Patients removable denture . 4 . Patients malignant blood disease . 5 . History use cytotoxic drug biological immunosuppressant ( TNFÎ± inhibitor ) . 6 . Had use clinical study drug 28 day enrollment . 7 . Had use clinical study drug 28 day enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>